In a regulatory filing, Immunome (IMNM) disclosed that its CTO Philip Tsai bought 12.3K shares of common stock on March 24th in a total ...

Investment analysts at Wedbush upped their Q1 2025 earnings per share estimates for shares of Immunome in a research report ...

Stephens restated their overweight rating on shares of Immunome (NASDAQ:IMNM – Free Report) in a research note released on ...

Immunome’s (IMNM) efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., President and Chief ...

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago. These figures are ...

Full Year 2024 Results Key Financial Results Net loss: US$293.0m (loss widened by 174% from ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform recommendation. Analyst Price Forecast Suggests 250.92% Upside As of March 4, ...

Projected cash runway extends into 2027 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended ...